These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 34011529)

  • 1. A Novel Maintenance Therapeutic for Opioid Use Disorder.
    Youngblood B; Li K; Gehlert DR; Medina JC; Schwartz N
    J Pharmacol Exp Ther; 2021 Aug; 378(2):133-145. PubMed ID: 34011529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
    Cisewski DH; Santos C; Koyfman A; Long B
    Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance medication for opiate addiction: the foundation of recovery.
    Bart G
    J Addict Dis; 2012; 31(3):207-25. PubMed ID: 22873183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder.
    Fipps DC; Oesterle TS; Kolla BP
    Semin Neurol; 2024 Aug; 44(4):441-451. PubMed ID: 38848746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
    Mannelli P; Douaihy AB; Zavod A; Legedza A; Akerman SC; Sullivan MA
    Am J Drug Alcohol Abuse; 2021 Nov; 47(6):753-759. PubMed ID: 34752714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
    Szczesniak LM; Calleo VJ; Sullivan RW
    Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.
    Sadee W; Oberdick J; Wang Z
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32932935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-Free Signaling of G-Protein-Coupled Receptors: Relevance to μ Opioid Receptors in Analgesia and Addiction.
    Sadee W; McKew JC
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
    D'Onofrio G; Herring AA; Perrone J; Hawk K; Samuels EA; Cowan E; Anderson E; McCormack R; Huntley K; Owens P; Martel S; Schactman M; Lofwall MR; Walsh SL; Dziura J; Fiellin DA
    JAMA Netw Open; 2024 Jul; 7(7):e2420702. PubMed ID: 38976265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CE: Acute Pain Management for People with Opioid Use Disorder.
    Broglio K; Matzo M
    Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
    Chalhoub RM; Kalivas PW
    Drugs; 2020 Oct; 80(15):1509-1524. PubMed ID: 32776315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
    Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.
    Mannelli P; Peindl KS; Lee T; Bhatia KS; Wu LT
    Curr Drug Abuse Rev; 2012 Mar; 5(1):52-63. PubMed ID: 22280332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
    Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
    Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in the Treatment of Opioid Use Disorder.
    Kuppalli S; Seth R; Orhurhu V; Urits I; Kaye AD; Hunter C; Gulati A; Adekoya P; Kaye AM; Jones MR
    Curr Pain Headache Rep; 2021 Mar; 25(4):23. PubMed ID: 33693999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.